|

A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma

RECRUITINGPhase 4Sponsored by Eli Lilly and Company
Actively Recruiting
PhasePhase 4
SponsorEli Lilly and Company
Started2025-05-20
Est. completion2030-05
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations18 sites
View on ClinicalTrials.gov →

NCT06876662

Summary

Study J2N-MC-JZ01 (JZ01) is an individual-study appendix (ISA) under master protocol J2N-MC-JZNY, and represents participants from the completed originator study, clinical study LOXO-BTK-18001/J2N-OX-JZNA. Participants in the originator study will have the opportunity to continue their assigned study intervention or continue their follow-up visits by transitioning to this study. This study will evaluate the long-term safety and efficacy of pirtobrutinib.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Are currently enrolled and active in the originator study, LOXO-BTK-18001. A participant is considered active in the study if they are:

  * receiving study intervention
  * in the short-term follow-up period, or
  * in the long-term follow-up period

Exclusion Criteria:

* Were a participant in the Phase 1b cohort of Study LOXO-BTK-18001

Conditions3

CancerChronic Lymphocytic LeukemiaNon-hodgkin Lymphoma

Locations18 sites

Sylvester Comprehensive Cancer Center
Miami, Florida, 33136-1002
954-265-6549
Florida Cancer Specialists
Sarasota, Florida, 34232-6422
941-377-9993
The Emory Clinic
Atlanta, Georgia, 30322-1013
404-778-3708
Northwestern University
Chicago, Illinois, 60611-3013
312-908-5250
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115
617-632-5847

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.